Estrogen receptor (ER)-negative breast cancers are a group of tumors with poor prognosis
and fewer cancer prevention and treatment strategies compared to ER-positive tumors. The …

The management of patients with carcinoma of the breast has changed enormously in the
last 20 years, for a variety of reasons. The number of therapeutic options has widened …

Intraductal epithelial proliferations of the breast are at present classified into three groups;
distinction is made histologically and clinically between usual epithelial hyperplasia and …

The genomic landscape of breast cancer is complex, and inter-and intra-tumour
heterogeneity are important challenges in treating the disease. In this study, we sequence …

Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-
mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) …

We have examined basal and luminal cell cytokeratin expression in 1944 cases of invasive
breast carcinoma, using tissue microarray (TMA) technology, to determine the frequency of …

Recent studies on gene molecular profiling using cDNA microarray in a relatively small
series of breast cancer have identified biologically distinct groups with apparent clinical and …

The complex refractive indices of freshly excised healthy breast tissue and breast cancers
collected from 20 patients were measured in the range of 0.15-2.0 THz using a portable …

Background Estrogen receptor (ER)-negative breast cancer specimens are predominantly of
high grade, have frequent p53 mutations, and are broadly divided into HER2-positive and …

Background Initial results of the UK/ANZ DCIS (UK, Australia, and New Zealand ductal
carcinoma in situ) trial suggested that radiotherapy reduced new breast events of ipsilateral …